Company Timeline & Milestones

How We Got Here… One Patient at a Time!

Established the same year the human genome was first sequenced in 2000, Genomic Health was founded with a bold mission: to harness the potential of the genomic revolution to eliminate the “one-size-fits-all” approach to cancer treatment. Select a date below to see the history of Genomic Health unfold.

Oncotype IQ Genomic Intelligence Platform Helps More than 700,000 Patients Worldwide

The Oncotype IQ portfolio of tests for invasive breast cancer, DCIS breast cancer, colon cancer, lung cancer and prostate cancer help more than 700,000 patients make more informed treatment decisions around the world.


Topline Study Results Demonstrate Oncotype DX Predicts Prostate Cancer Metastasis and Mortality

Oncotype DX Genomic Prostate Score becomes only test validated to measure all four critical features of tumor aggressiveness. Read more


Unsurpassed Amount of Prospective Clinical Outcomes Results Reinforce Oncotype DX’s Unmatched Value in Personalizing Breast Cancer Treatment

Multiple large independent studies in over 63,000 breast cancer patients across four countries highlight superior clinical evidence for Oncotype DX in identifying which patients with node-negative and node-positive invasive breast cancer should be treated with chemotherapy. Read more


Strategic Collaboration with Epic Sciences to Deliver AR-V7 Liquid Biopsy Test Expands Oncotype IQ Portfolio

Exclusive agreement to commercialize Epic Sciences' novel AR-V7 liquid biopsy test to predict treatment response in metastatic prostate cancer, furthering Genomic Health’s vision to serve patients across their cancer journey. Read more


Launch of Company’s First Liquid Biopsy Test

Oncotype SEQ liquid biopsy mutation panel uses next-generation sequencing to identify and assess actionable genomic alterations in a panel of 17 select genes to inform the treatment of stage IV solid tumors. Read more


Plan B Trial Reports Clinical Outcomes

One of Europe's largest contemporary adjuvant breast cancer trials conducted by the West German Study Group in Germany showed that Oncotype DX accurately predicted which patients can be spared chemotherapy even when traditional factors indicate higher-risk disease and their disease-free survival five years after the diagnosis. Read More


Oncotype DX included in German National Cancer Guidelines with 1A Level of Evidence

First and only multi-gene breast cancer test to be included in German National Cancer Guidelines following publication of multiple large prospective outcomes studies. Read more

SEER Registry Outcomes Results

Prospective outcomes results from a large population observational study in more than 44,500 breast cancer patients show that patients with Recurrence Score less than 18 have excellent breast cancer survival at five years. Read More


TailorX Outcomes Results Published

Large TAILORx outcomes study demonstrates 99% of patients with low Oncotype DX Recurrence Score results were free of breast cancer recurrence following five years of hormone therapy alone. Read More


Clalit Health Services Study

Prospective clinical outcomes results from Clalit Health Services, the largest Health Maintenance Organization in Israel, reinforces ability of Oncotype DX to predict clinical outcomes in patients with low and intermediate Recurrence Score results. Read more


Oncotype DX Prostate Cancer Test Covered by Medicare

Oncotype DX prostate cancer test receives Medicare coverage for qualifying patients, bringing precision medicine to nearly 60,000 prostate cancer patients in the United States. Read More


Bladder Cancer Liquid Biopsy Test Advances

Genomic Health presents positive proof-of-concept data for bladder cancer liquid biopsy test. Read More


UK Patients Gain Access to Oncotype DX Breast Cancer Test

National Health Service (NHS) England agrees to access program for the Oncotype DX breast cancer test following NICE’s exclusive recommendation. Read More

Liquid Biopsy Pipeline Expansion

Genomic Health advances development of liquid biopsy-based cancer tests to detect breast and bladder cancers in blood and urine samples. Read more


Oncotype DX Helps More than 500,000 Patients

The Oncotype DX portfolio of tests for invasive breast cancer, DCIS breast cancer, colon cancer and prostate cancer help more than 500,000 patients make more informed treatment decisions around the world.

Oncotype DX Prostate Cancer Test Launched

Genomic Health launches the Oncotype DX prostate cancer test, a biopsy-based genomic test that, when combined with other clinical measures, can be used to predict the aggressiveness of a low risk prostate cancer, helping men and their doctors decide whether active surveillance or more immediate invasive treatment, such as surgery, is necessary. Read More

Oncotype DX Genomic Prostate Score


Oncotype DX Breast Cancer Test Included in ESMO Guidelines

The European Society for Medical Oncology (ESMO) includes the Oncotype DX Breast Cancer Assay in its treatment guidelines.

Next Generation Sequencing Program Accelerates

Next Generation Sequencing (NGS) program accelerates clinical development studies to examine both RNA-Seq expression and mutation analysis. Read More

Oncotype DX Breast Cancer Test for DCIS Launched

Genomic Health launches the Oncotype DX breast cancer test for DCIS patients, the first clinically validated genomic assay to provide an individualized prediction of the 10-year risk of local recurrence to help guide treatment decision-making in patients with ductal carcinoma in situ (DCIS). Read More

Oncotype DX Breast DCIS Score


Oncotype DX Colon Cancer Test Covered by Medicare

Medicare establishes coverage for the Oncotype DX colon cancer test. Read More


Oncotype DX Breast Cancer Test Recognized by St. Gallen Expert Consensus

The 12th St. Gallen International Breast Cancer Conference Expert Panel recognizes the Oncotype DX breast cancer test for its ability to provide not only prognostic, but also predictive information. Read More


Genomic Health UK Headquarters established in London

International Headquarters Established

Genomic Health opens international headquarters in Geneva, Switzerland.


Oncotype DX Colon Cancer Test Launched

Genomic Health announces the global launch of the Oncotype DX colon cancer test to help patients seeking stage II colon cancer treatment determine if they have aggressive disease. Read More

Oncotype DX Colon Recurrence Score

Oncotype DX Breast Cancer Test Helps More than 100,000 Patients

Genomic Health announces the Oncotype DX breast cancer test has helped guide individualized treatment decisions for more than 100,000 patients worldwide. Read More

Oncotype DX Breast Cancer Test Included in NCCN Guidelines

The National Comprehensive Cancer Network (NCCN) includes Oncotype DX in its 2008 Breast Cancer Treatment Guidelines. Read More

Oncotype DX Breast Cancer Test Included in ASCO Guidelines

The American Society of Clinical Oncology (ASCO) includes the Oncotype DX breast cancer test in its updated guidelines on the use of breast cancer tumor markers. Read More


Oncotype DX Breast Cancer Test Validated for Node-Positive Patients

Genomic Health presents positive results at ASCO from its first study investigating the Oncotype DX breast cancer test in node-positive breast cancer patients. Read More

Oncotype DX Breast Cancer Test Covered by Medicare

Medicare establishes reimbursement for the Oncotype DX breast cancer test for qualifying patients. Read More

Genomic Health Completes IPO

Genomic Health completes initial public offering. Read More

Oncotype DX Breast Cancer Test Launched

Genomic Health launches the Oncotype DX breast cancer test that quantifies the likelihood of breast cancer recurrence for early-stage breast cancer patients, and also predicts the magnitude of chemotherapy benefit.

Oncotype DX Breast Recurrence Score 


NSABP Study Validates Oncotype DX 21-Gene Panel

The National Surgical Adjuvant Breast and Bowel Project (NSABP) and Genomic Health, Inc. announce positive results of a new study demonstrating that the Oncotype DX 21-gene panel quantifies the likelihood of breast cancer recurrence for a large portion of early stage breast cancer patients, and also predicts the magnitude of chemotherapy benefit in patients from the B-20 study. Read More

NSABP Study Validates Genomic Health’s Ability to Quantify Recurrence

The National Surgical Adjuvant Breast and Bowel Project (NSABP) and Genomic Health, Inc. announces that their large, prospective B-14 clinical trial met its defined endpoints and validated that Genomic Health’s unique breast cancer assay can accurately quantify the likelihood of breast cancer recurrence in a large segment of newly diagnosed breast cancer patients. Read More

Proof of Concept Completed

Genomic Health completes proof of concept studies, confirming the company’s ability to successfully obtain gene expression analysis profiles from formalin-fixed paraffin-embedded (FPET) tumor tissue.

Genomic Health Founded in Redwood City, California

Inspired by a close friend’s cancer diagnosis, Randy Scott founds Genomic Health in Redwood City, California with the goal of developing high-value diagnostics to enable more personalized cancer treatment decisions based on the genomic activity within a patient’s individual tumor.

My Colon Cancer Coach